Impact of naturally occurring polymorphisms on the structure of HIV-1 integrase that can influence dolutegravir binding among subtypes A1 and D.
Fuente:
Zenodo
Saved in:
| Main Author: | Ssekagiri, Alfred |
|---|---|
| Format: | Recurso digital |
| Published: |
Zenodo
2026
|
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
A nanoemulsified formulation of dolutegravir and epigallocatechin gallate inhibits HIV‐1 replication in cellular models
by: Shraddha Y. Gaikwad, et al.
Published: (2024)
by: Shraddha Y. Gaikwad, et al.
Published: (2024)
Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
by: C. Hu, et al.
Published: (2025)
by: C. Hu, et al.
Published: (2025)
Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use
by: Kathleen J. Pincus, et al.
Published: (2025)
by: Kathleen J. Pincus, et al.
Published: (2025)
Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed
by: C. Piñeiro, et al.
Published: (2024)
by: C. Piñeiro, et al.
Published: (2024)
Therapeutic drug monitoring of dolutegravir in children and adolescents living with HIV: A retrospective study
by: E. Pilote, et al.
Published: (2025)
by: E. Pilote, et al.
Published: (2025)
A preliminary analysis of the impact of pharmacogenetic variation on bictegravir and dolutegravir concentrations in individuals with HIV and tuberculosis
by: A. Naidoo, et al.
Published: (2025)
by: A. Naidoo, et al.
Published: (2025)
Simplifying explicit subtyping coercions in a polymorphic calculus with effects
by: Koprivec, Filip, et al.
Published: (2024)
by: Koprivec, Filip, et al.
Published: (2024)
Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts
by: Thierry Tiendrebeogo, et al.
Published: (2024)
by: Thierry Tiendrebeogo, et al.
Published: (2024)
Rethinking HIV treatment: How non‐integrase strand regimens may hold the key to better immune health
by: Bogusz Aksak‐Wąs, et al.
Published: (2025)
by: Bogusz Aksak‐Wąs, et al.
Published: (2025)
Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir
by: Pierluigi Francesco Salvo, et al.
Published: (2025)
by: Pierluigi Francesco Salvo, et al.
Published: (2025)
High peak viraemia followed by spontaneous HIV‐1 control in women living with HIV‐1 subtype A1 in East Africa
by: Yifan Li, et al.
Published: (2025)
by: Yifan Li, et al.
Published: (2025)
Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
by: Inés Suárez‐García, et al.
Published: (2025)
by: Inés Suárez‐García, et al.
Published: (2025)
Blood pressure and metabolic outcomes after efavirenz‐ or dolutegravir‐based therapy started in acute HIV infection
by: Phillip Chan, et al.
Published: (2025)
by: Phillip Chan, et al.
Published: (2025)
Clinical outcomes of switching to dolutegravir/lamivudine dual therapy in people living with HIV: A single‐centre retrospective study
by: D. Yagci‐Caglayik, et al.
Published: (2025)
by: D. Yagci‐Caglayik, et al.
Published: (2025)
Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná
by: Bárbara Thaís Poliselo de Sá
Published: (2022)
by: Bárbara Thaís Poliselo de Sá
Published: (2022)
Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
by: Santiago Moreno Guillén
Published: (2017)
by: Santiago Moreno Guillén
Published: (2017)
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens
by: Baralee Punyawudho, et al.
Published: (2024)
by: Baralee Punyawudho, et al.
Published: (2024)
Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
by: C. Hu, et al.
Published: (2025)
by: C. Hu, et al.
Published: (2025)
Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study
by: Axel Ursenbach, et al.
Published: (2024)
by: Axel Ursenbach, et al.
Published: (2024)
No increased risk of tuberculosis‐related immune reconstitution inflammatory syndrome with integrase inhibitor‐based antiretroviral therapy in people withHIV with profound immunosuppression
by: Chi Kuen Chan, et al.
Published: (2024)
by: Chi Kuen Chan, et al.
Published: (2024)
Novel diarylpyrimidine subtypes as HIV‐1 nonnucleoside reverse transcriptase inhibitors with improved resistance profile
by: Zhengqiang Wang
Published: (2024)
by: Zhengqiang Wang
Published: (2024)
APOL1 polymorphisms are not influencing acute coronary syndrome risk in Czech males
by: Jaroslav A. Hubacek, et al.
Published: (2024)
by: Jaroslav A. Hubacek, et al.
Published: (2024)
Improvements in cognitive performance switching from efavirenz‐ to dolutegravir‐based antiretroviral therapy in South African people with HIV: the CONNECT study
by: Sam Nightingale
Published: (2025)
by: Sam Nightingale
Published: (2025)
“Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study”
by: Félix Gutiérrez
Published: (2024)
by: Félix Gutiérrez
Published: (2024)
Genetic polymorphisms influencing antihypertensive drug responses
by: Jana El Cheikh, et al.
Published: (2024)
by: Jana El Cheikh, et al.
Published: (2024)
The influence of the Casimir effect on the binding potential for 3D wetting
by: Squarcini, Alessio, et al.
Published: (2025)
by: Squarcini, Alessio, et al.
Published: (2025)
Jacquetium: a new, naturally-occurring chemical element
by: Jacquet, Emmanuel
Published: (2025)
by: Jacquet, Emmanuel
Published: (2025)
How can embedding models bind concepts?
by: Uselis, Arnas, et al.
Published: (2026)
by: Uselis, Arnas, et al.
Published: (2026)
Unveiling the influence of crystal structure polymorphs on radiation shielding properties: A case study of SiO 2
by: Ziad Khattari
Published: (2024)
by: Ziad Khattari
Published: (2024)
Correction to “Genetic polymorphisms influencing antihypertensive drug responses”
Published: (2025)
Published: (2025)
Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin‐based regimen: A retrospective observational case series
by: Yanyun Dou, et al.
Published: (2024)
by: Yanyun Dou, et al.
Published: (2024)
Characteristics and influencing factors of anticipated HIV stigma among HIV‐negative/unknown MSM in China: A regression mixture model
by: Zhenwei Dai, et al.
Published: (2024)
by: Zhenwei Dai, et al.
Published: (2024)
Influence of age and co‐medication on dolutegravir glucuronidation in paediatric patients
by: Tom G. Jacobs, et al.
Published: (2024)
by: Tom G. Jacobs, et al.
Published: (2024)
The ber pathway genes and pon1 polymorphism: influence on dna damage in agriculture-exposed workers
by: Paula Rohr
Published: (2006)
by: Paula Rohr
Published: (2006)
Diagnosis of naturally occurring canine hypercortisolism: survey of Australian veterinarians
by: MA Wray, et al.
Published: (2025)
by: MA Wray, et al.
Published: (2025)
Electrophoretic assembly of naturally occurring humic substances as thin films
Published: (2003)
Published: (2003)
Trends in the electronic structure of borophene polymorphs
by: Osorio, Alam, et al.
Published: (2025)
by: Osorio, Alam, et al.
Published: (2025)
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes
by: Anta L, et al.
Published: (2025)
by: Anta L, et al.
Published: (2025)
Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV : Data from the COMBINE ‐2 study
by: Cristina Mussini, et al.
Published: (2026)
by: Cristina Mussini, et al.
Published: (2026)
The influence of international labour standards: possibilities and performance
by: Ernest Alfred Landy
Published: (1970)
by: Ernest Alfred Landy
Published: (1970)
Similar Items
-
A nanoemulsified formulation of dolutegravir and epigallocatechin gallate inhibits HIV‐1 replication in cellular models
by: Shraddha Y. Gaikwad, et al.
Published: (2024) -
Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
by: C. Hu, et al.
Published: (2025) -
Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use
by: Kathleen J. Pincus, et al.
Published: (2025) -
Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed
by: C. Piñeiro, et al.
Published: (2024) -
Therapeutic drug monitoring of dolutegravir in children and adolescents living with HIV: A retrospective study
by: E. Pilote, et al.
Published: (2025)